Novavax, Inc. (NVAX) has a Market value of 308.05 Million

Gladys Abbott
May 20, 2017

NVAX has been the subject of a number of recent research reports. Overall, the share price is down -14.76% year to date.

Price targets show what analysts believes a stock will be worth at the end of a certain time period. To make a proper assessment, investors seek a sound estimate of this year's and next year's earnings per share (EPS), as well as a strong sense of how much the company will earn even farther down the road.

Investors and Traders continue to monitor technical levels of shares of Novavax, Inc. Finally, JPMorgan Chase & Co. increased its position in shares of Novavax by 110.5% in the third quarter. Investors measure stock performance on the basis of a company's earnings power. Piermont Capital Management Inc. increased its stake in shares of Novavax by 9.2% in the third quarter. Noting its average daily volume at 3.41 million shares each day over the month, this signifies a pretty significant change over the norm. Overall, 7.41 Million shares exchanged hands versus its average trading volume of 6.56 Million shares. The Company has 52-week high of $8.49 and 52-week low of $0.73. The stock's current distance from 20-Day Simple Moving Average (SMA20) is 26.16% where SMA50 and SMA200 are 3.57% and -52.85% respectively. The stock's market cap is $308.03 million.

More news: Sharapova vows to 'rise up again' after French Open snub

Novavax, Inc. (NASDAQ:NVAX) has announced its financial results for the first quarter of 2017. The biopharmaceutical company reported ($0.16) EPS for the quarter, topping the Zacks' consensus estimate of ($0.18) by $0.02. Novavax had a negative net margin of 1,908.41% and a negative return on equity of 189.14%.

Novavax Inc (NASDAQ:NVAX)'s revenue estimates for the current quarter are $5.7 Million according to 6 number of analysts, for the current quarter the company has high revenue estimates of $6.6 Million in contradiction of low revenue estimates of $4.5 Million. However the company reported $-0.29 earnings per share for the same quarter during previous year. The firm's revenue for the quarter was down 7.7% compared to the same quarter a year ago. This Beta value of Novavax, Inc. Cantor Fitzgerald reaffirmed a "neutral" rating and issued a $2.00 target price on shares of Novavax in a report on Wednesday, March 1st.

Additionally on 9/20/16 Chardan Capital "Maintained" Novavax Inc (NASDAQ:NVAX) to Neutral setting price target at $1.5 and on 9/19/16 Citigroup "Maintained" the stock to Neutral at $1.5. Seven analysts have rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company's stock. When we look at the Volatility of the company, Week Volatility is at 12.89% whereas Month Volatility is at 7.93%. The stock is presently trading up its SMA-50 of $124.06. The Return on Investment (ROI) ratio of Novavax, Inc. State Street Corp now owns 19,971,040 shares of the biopharmaceutical company's stock worth $25,163,000 after buying an additional 9,947,481 shares during the last quarter. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders bought 105,000 shares of company stock valued at $90,800 over the last ninety days. Corporate insiders own 3.50% of the company's stock. In a statement, Novavax President and CEO Stanley C. Erck said the company made a lot of progress in the implementation of key clinical studies of the RSV F vaccine for maternal immunization to infants as well as for use in adults.

Other reports by LeisureTravelAid

Discuss This Article